Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | MIF | P14174 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542970 | 1.00 | ESR1 (0.63) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL5024580 | 1.00 | ESR1 (0.63) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL5360147 | 0.86 | ESR1 (0.51) | ESR1ESR2MIFSLC7A5TAAR1 | |
| SCHEMBL3694538 | 0.86 | ESR1 (0.51) | ESR1ESR2MIFSLC7A5TAAR1 | |
| SCHEMBL3535230 | 0.85 | ESR1 (0.58) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL13792677 | 0.85 | ESR1 (0.58) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL3535227 | 0.85 | ESR1 (0.58) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL3993110 | 0.85 | ESR1 (0.58) | ESR1ESR2MIFKMT2ANPSR1 | |
| SCHEMBL4455242 | 0.84 | LDHA (0.59) | — | |
| SCHEMBL16451001 | 0.84 | ESR1 (0.45) | ESR1ESR2MIFLNPEPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114080390-A | Synthesis of coelenterazine | 国际纸业公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3830088-A1 | SYNTHESIS OF COELENTERAZINE | International Paper Company (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112368286-A | Synthesis of coelenterazine | 国际纸业公司 | 2021-02-12 | — | — | CN | disclosed |
| US-8558009-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2013-10-15 | — | — | US | disclosed |
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| EP-1414439-B1 | NOVEL PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILA HEALTHCARE LTD (IN) | 2011-05-04 | — | — | EP | disclosed |
| CN-100450477-C | Novel pyrrole compound with blood fat and cholesterol reducing activity, preparation method thereof, pharmaceutical composition containing same and medical application thereof | CADILA HEALTHCARE LTD (IN) | 2009-01-14 | — | — | CN | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| EP-1124808-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1000938-A1 | Heterocyclic compounds as pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
| US-6048883-A | HYPOGLYCEMIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-11 | — | — | US | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| US-5869495-A | TREATMENT AND/OR PROPHYLAXIS OF HYPERGLYCAEMIA | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-02-09 | — | — | US | disclosed |
| US-5827865-A | TREATMENT AND-OR PROPHYLAXIS OF HYPERGLYEMIA | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0648212-A1 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL | SMITHKLINE BEECHAM PLC (GB) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994001420-A1 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL | SMITHKLINE BEECHAM PLC (GB) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CETP, LIPA, LIPC | ESR1 4634/4885ESR2 3324/4885MIF 2944/4885 |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | ESR1 4680/4885ESR2 4796/4885MIF 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.